- Home
- APLM vs CDIO Comparison
APLM vs CDIO Comparison
Compare APLM & CDIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLM
- CDIO
- Stock Information
- Founded
- APLM 2016
- CDIO 2017
- Country
- APLM United States
- CDIO United States
- Employees
- APLM N/A
- CDIO N/A
- Industry
- APLM Blank Checks
- CDIO Biotechnology: Commercial Physical & Biological Resarch
- Sector
- APLM Finance
- CDIO Health Care
- Exchange
- APLM Nasdaq
- CDIO Nasdaq
- Market Cap
- APLM 6.1M
- CDIO 6.4M
- IPO Year
- APLM N/A
- CDIO N/A
- Fundamental
- Price
- APLM $5.80
- CDIO $3.82
- Analyst Decision
- APLM
- CDIO Buy
- Analyst Count
- APLM 0
- CDIO 1
- Target Price
- APLM N/A
- CDIO $60.00
- AVG Volume (30 Days)
- APLM 47.7K
- CDIO 41.6K
- Earning Date
- APLM 08-18-2025
- CDIO 08-26-2025
- Dividend Yield
- APLM N/A
- CDIO N/A
- EPS Growth
- APLM N/A
- CDIO N/A
- EPS
- APLM N/A
- CDIO N/A
- Revenue
- APLM $198,000.00
- CDIO $19,902.00
- Revenue This Year
- APLM $415.15
- CDIO $1,434.82
- Revenue Next Year
- APLM N/A
- CDIO $4,661.91
- P/E Ratio
- APLM N/A
- CDIO N/A
- Revenue Growth
- APLM N/A
- CDIO N/A
- 52 Week Low
- APLM $4.47
- CDIO $3.22
- 52 Week High
- APLM $35.98
- CDIO $53.10
- Technical
- Relative Strength Index (RSI)
- APLM 47.28
- CDIO 44.76
- Support Level
- APLM $5.41
- CDIO $3.37
- Resistance Level
- APLM $6.38
- CDIO $3.88
- Average True Range (ATR)
- APLM 0.44
- CDIO 0.34
- MACD
- APLM -0.01
- CDIO -0.03
- Stochastic Oscillator
- APLM 31.20
- CDIO 33.38
About APLM Apollomics Inc.
Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.
About CDIO Cardio Diagnostics Holdings Inc. Common stock
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases. The company offers three AI-powered solutions for the risk assessment, detection, management, and monitoring of coronary heart diseases. These solutions are Epi+Gen CHD, a symptomatic CHD risk assessment clinical blood test targeting CHD events; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform coupled to the Epi+Gen CHD and PrecisionCHD tests that provide personalized insights by linking the epigenetic and genetic biomarkers evaluated by these tests to the drivers of coronary heart disease.